{
    "clinical_study": {
        "@rank": "15103", 
        "arm_group": {
            "arm_group_label": "Raltegravir", 
            "arm_group_type": "Other", 
            "description": "Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy."
        }, 
        "brief_summary": {
            "textblock": "This is a 24-week, one arm, open-label, interventional, non-comparative multicenter study to\n      evaluate lipid changes in HIV infected women with hyperlipidemia on boosted PI based regimen\n      after switching their boosted PI to raltegravir at standard dosage with 400mg twice daily.\n\n      This study aims to study the effect on metabolic profiles by switching hyperlipidemic HIV\n      infected women from a PI based regimen to raltegravir."
        }, 
        "brief_title": "Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Hyperlipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented HIV-1 infection in female patients, age \u226518 years\n\n          -  Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral\n             agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI)\n             for at least the previous 6 months\n\n          -  Plasma HIV viral load <50 copies/ml on current boosted PI containing regimen for \u2265 6\n             months prior to study entry\n\n          -  Fasting LDL cholesterol >130 mg/dl\n\n          -  Fasting triglycerides <450 mg/dl\n\n        Exclusion Criteria:\n\n          -  History of virological failure during previous antiretroviral therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097108", 
            "org_study_id": "AGMT_HIV1"
        }, 
        "intervention": {
            "arm_group_label": "Raltegravir", 
            "intervention_name": "Raltegravir", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV infection", 
            "Raltegravir", 
            "Switch", 
            "Hyperlipidemia", 
            "Women"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "n.taylor@salk.at", 
                    "last_name": "Ninon Taylor, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Salzburg", 
                        "country": "Austria", 
                        "zip": "5020"
                    }, 
                    "name": "PMU Salzburg"
                }, 
                "investigator": {
                    "last_name": "Richard Greil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "armin.rieger@meduniwien.ac.at", 
                    "last_name": "Armin Rieger, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }, 
                    "name": "AKH Wien"
                }, 
                "investigator": {
                    "last_name": "Armin Rieger, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "brigitte.schmied@wienkav.at", 
                    "last_name": "Brigitte Schmied, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1140"
                    }, 
                    "name": "Ottto Wagner Spital"
                }, 
                "investigator": {
                    "last_name": "Brigitte Schmied, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "One Arm, Open Label, Interventional, Non-comparative Study to Assess Changes in Lipids and Lipoproteins in HIV Infected Women With Hyperlipidemia After Switch From Boosted Protease Inhibitor to Raltegravir", 
        "overall_official": {
            "affiliation": "PMU Salzburg", 
            "last_name": "Richard Greil, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A reduction of > 5% in the plasma concentration of direct LDL cholesterol from baseline to week 12 or > 10% reduction of total cholesterol or reduction of lipid lowering agents is expected. Reduction of lipid lowering agents is defined as reduction due to amelioration of lipid profiles and does not include reduction due to side effects or other toxicity issues.", 
            "measure": "Reduction in the plasma concentration of cholesterol", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097108"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "changes from baseline in total cholesterol, triglycerides and HDL cholesterol over time", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "evaluate risk reduction of cardiovascular risk during the treatment period according to Framingham risk score", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Arbeitsgemeinschaft medikamentoese Tumortherapie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}